Research programme: cancer diagnostics - Patrys/Macquarie University/Minomic International

Drug Profile

Research programme: cancer diagnostics - Patrys/Macquarie University/Minomic International

Alternative Names: Nanocrystal fluorescent technology - Cancer diagnostics; Super dot nanocrystal-labelled PAT-SM6

Latest Information Update: 20 Jun 2016

Price : $50

At a glance

  • Originator Macquarie University; Minomic International; Patrys
  • Class Monoclonal antibody diagnostics
  • Mechanism of Action Single-photon emission-computed tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 14 Jun 2016 Preclinical trials in Cancer (Diagnosis) in Australia (IV) before June 2016
  • 10 Jul 2013 Early research in Cancer (diagnosis) in Australia (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top